Nathan Brinkman

Merck and Co. (MRK) - Q4 2025 Review

Pressing Pause in 2026

Sanofi (SNY) FY 2025 Review

Boring is the new beautiful

Moderna (MRNA) - Q4 2025 Review

MRNA x Vaccine Regulation

Inocyte (INCY) - Q4 2025 Review

Wave 3 or Value Trap? Incyte After Q4

Novo Nordisk (NVO) - Q4 2025 Review

DISCLAIMER: This note is intended for US recipients only and,

Regeneron (REGN) – Q4 2025 Review

The Pipeline's Gotta Hold!

Arbutus Biopharma (ABUS) - Clinical-Stage, IP-Centric Biopharma

A Binary Biotech Play?